[1]成志烜.分化型甲状腺癌经腔镜手术治疗后出现复发转移的危险因素分析[J].医学信息,2024,37(19):94-97.[doi:10.3969/j.issn.1006-1959.2024.19.017]
　CHENG Zhixuan.Analysis of Risk Factors for Recurrence and Metastasis of Differentiated Thyroid Carcinoma After Endoscopic Surgery[J].Journal of Medical Information,2024,37(19):94-97.[doi:10.3969/j.issn.1006-1959.2024.19.017]
点击复制

分化型甲状腺癌经腔镜手术治疗后出现复发转移的危险因素分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年19期
页码:
94-97
栏目:
论著
出版日期:
2024-10-01

文章信息/Info

Title:
Analysis of Risk Factors for Recurrence and Metastasis of Differentiated Thyroid Carcinoma After Endoscopic Surgery
文章编号:
1006-1959（2024）19-0094-04
作者:
成志烜
万载县人民医院甲乳外科，江西 万载 336199
Author(s):
CHENG Zhixuan
Department of Thyroid and Breast Surgery,Wanzai County People’s Hospital,Wanzai 336199,Jiangxi,China
关键词:
分化型甲状腺癌; 腔镜手术; 复发转移; 滤泡状甲状腺癌; 术前淋巴结转移
Keywords:
Differentiated thyroid carcinoma; Endoscopic surgery; Recurrence and metastasis; Follicular thyroid carcinoma; Preoperative lymph node metastasis
分类号:
R736.1
DOI:
10.3969/j.issn.1006-1959.2024.19.017
文献标志码:
A
摘要:
目的 分析分化型甲状腺癌（DTC）经腔镜手术治疗后出现复发转移的危险因素。方法 以2019年12月-2021年12月万载县人民医院行腔镜手术治疗的112例DTC患者为研究对象。截至2023年9月，其术后复发转移者共32例，设为复发转移组，未复发转移者共80例，设为未复发转移组，收集其基线资料，通过单因素及多因素Logistic分析DTC经腔镜手术治疗后出现复发转移的危险因素。结果 复发转移组与未复发转移组年龄、病理类型、肿瘤直径、临床分期、术前淋巴结转移、病灶数目、术后口服甲状腺素比较，差异有统计学意义（P＜0.05），其中复发转移组年龄≥45岁、肿瘤类型FTC、肿瘤直径≥5 cm、临床分期Ⅲ~Ⅳ期、术前淋巴结转移、多发病灶、术后未口服甲状腺素患者占比高于未复发转移组。经Logistic回归分析显示，年龄≥45岁（OR：2.932，95%CI：1.208~4.217）、肿瘤直径≥5 cm（OR：2.653，95%CI：1.054~3.435）、临床分期Ⅲ~Ⅳ期（OR：2.134，95%CI：1.129~3.741）、术前淋巴结转移（OR：2.241，95%CI：1.632~4.063）、多发病灶（OR：2.173，95%CI：1.339~3.648）是DTC患者经腔镜手术治疗后出现复发转移的独立危险因素（P＜0.05）。结论 DTC患者经腔镜手术治疗后发生复发转移与年龄、肿瘤直径、临床分期、术前淋巴结转移、多发病灶密切相关。
Abstract:
Objective To analyze the risk factors of recurrence and metastasis of differentiated thyroid carcinoma (DTC) after endoscopic surgery.Methods A total of 112 patients with DTC who underwent endoscopic surgery in Wanzai County People’s Hospital from December 2019 to December 2021 were enrolled in the study. As of September 2023, a total of 32 patients with postoperative recurrence and metastasis were set as recurrence and metastasis group, and a total of 80 patients without recurrence and metastasis were set as non-recurrence and metastasis group. The baseline data were collected, and the risk factors of recurrence and metastasis of DTC after endoscopic surgery were analyzed by univariate and multivariate Logistic analysis.Results There were statistically significant differences in age, pathological type, tumor diameter, clinical stage, preoperative lymph node metastasis, number of lesions, and postoperative oral thyroxine between the recurrence and metastasis group and the non-recurrence and metastasis group (P<0.05), while the proportion of patients with age ≥45 years old, tumor type FTC, tumor diameter ≥5 cm, clinical stage Ⅲ-Ⅳ, preoperative lymph node metastasis, multiple lesions, and postoperative non-oral thyroxine in the recurrence and metastasis group was higher than that in the non-recurrence and metastasis group. Logistic regression analysis showed that age≥45 years old (OR: 2.932, 95%CI: 1.208-4.217), tumor diameter ≥5 cm ( OR: 2.653, 95%CI: 1.054-3.435), clinical stage Ⅲ-Ⅳ (OR: 2.134, 95%CI: 1.129-3.741), preoperative lymph node metastasis (OR: 2.241, 95%CI: 1.632-4.063), multiple lesions (OR: 2.173, 95%CI: 1.339-3.648) were independent risk factors for recurrence and metastasis in DTC patients after endoscopic surgery (P<0.05).Conclusion Recurrence and metastasis of DTC patients after endoscopic surgery are closely related to age, tumor diameter, clinical stage, preoperative lymph node metastasis and multiple lesions.

参考文献/References:

[1]何辉,黄珊,陈灶萍.不同手术方式治疗分化型甲状腺癌的疗效及影响因素分析[J].海南医学,2019,30(14):1803-1806.[2]樊友本,邓先兆,伍波.儿童及青少年甲状腺癌术后复发危险因素及其处理[J].中国实用外科杂志,2022,42(6):658-661.[3]王纯娜,林珍妃,汪冬艳.经乳晕入路腔镜甲状腺手术治疗分化型甲状腺癌的疗效及术后复发因素分析[J].临床和实验医学杂志,2022,21(8):834-838.[4]王兴,李伟文,邵明涛,等.分化型甲状腺癌中央区淋巴结转移患者临床病理特征及转移危险因素分析[J].肿瘤研究与临床,2020,32(7):493-497.[5]王晓龙,廖观生,张志健,等.cN0期甲状腺癌术后复发、转移的发生率及相关因素分析[J].广州医科大学学报,2019,47(5):70-73.[6]中华人民共和国国家卫生健康委员会医政医管局.甲状腺癌诊疗指南(2022年版)[J].中国实用外科杂志,2022,42(12):1343-1357,1363.[7]苏亚丽,席丹丹.分化型甲状腺癌患者的临床特点及预后分析[J].癌症进展,2021,19(1):62-64.[8]曾兴玲,夏旭良,江志强.全腔镜下手术治疗对分化型甲状腺癌患者围术期指标、炎性因子及认知功能的影响[J].临床误诊误治,2021,34(2):88-92.[9]郭明皓,马悦心,组木热提·吐尔洪,等.分化型甲状腺癌肺转移危险因素及其对~(131)I治疗的疗效分析[J].四川医学,2020,41(12):1255-1259.[10]王源波,刘岩,刘哲,等.影响分化型甲状腺癌肺转移患者预后的临床因素[J].现代肿瘤医学,2020,28(20):3517-3520.[11]Pérez-Soto RH,Velázquez-Fernández D,Arellano-Gutiérrez G,et al.Preoperative and Postoperative Risk Stratification of Thyroid Papillary Microcarcinoma: A Comparative Study Between Kuma Criteria and 2015 American Thyroid Association Guidelines Risk Stratification[J].Thyroid,2020,30(6):857-862.[12]汪鑫,武晓娜,曹力钒,等.改良Miccoli手术治疗分化型甲状腺癌的疗效及术后复发的相关因素分析[J].癌症进展,2020,18(2):172-175.[13]张立阳,刘春浩,曹越,等.125例复发/持续性分化型甲状腺癌再次手术及其预后影响因素分析[J].中国癌症杂志,2019,29(6):412-417.[14]陆志峰,冯尚勇,顾学文,等.359例甲状腺癌患者临床特点及颈部淋巴结转移的相关因素[J].实用临床医药杂志,2018,22(21):61-64.[15]高立霓,张敏,杨大雁,等.分化型甲状腺癌术前原发肿物超声特征与术后颈部淋巴结转移的关系[J].中国普通外科杂志,2019,28(5):630-635.[16]杨超,王萌.分化型甲状腺癌骨转移的危险因素分析[J].实用癌症杂志,2019,34(5):815-817.[17]陈旭,姜吉.老年分化型甲状腺癌患者术后复发转移的影响因素[J].中国老年学杂志,2020,40(10):2076-2078.[18]柯创武,程俊萍,王健.影响老年分化型甲状腺癌患者预后的因素分析[J].临床肿瘤学杂志,2022,27(10):936-939.[19]南琳,才仁,林海,等.乌鲁木齐某三甲医院2017年-2019年甲状腺癌临床特征及颈部淋巴结转移危险因素分析[J].中国病案,2021,22(4):54-57.[20]Hu D,Zhou J,He W,et al.Risk factors of lateral lymph node metastasis in cN0 papillary thyroid carcinoma[J].World J Surg Oncol,2018,16(1):30.[21]谭学礼,刘轼初,钟晓玲,等.甲状腺微小乳头状癌中央区淋巴结转移复发相关因素研究分析[J].影像科学与光化学,2020,38(6):1032-1037.[22]杨元芳,赵焕,郝莉.分化型甲状腺癌患者术后复发转移的临床指标及相关影响因素分析[J].实用癌症杂志,2022,37(10):1619-1621,1631.[23]眭慧敏,刘杰蕊,王瞳,等.儿童及青少年分化型甲状腺癌远处转移的临床病理学危险因素分析[J].中国癌症杂志,2019,29(6):423-428.[24]岳璇弟,刘文亚,向玲,等.全腔镜甲状腺切除术治疗分化型甲状腺癌的效果及复发危险因素分析[J].解放军医药杂志,2021,33(6):30-34.[25]宋桂芳,苗恩君,顾建华,等.分化型甲状腺癌患者临床病理特征及中央区(Ⅵ区)淋巴结转移的危险因素分析[J].中华保健医学杂志,2021,23(4):370-372.

相似文献/References:

[1]崔艳钊,吴椿泉.甲状腺切除术治疗分化型甲状腺癌的疗效[J].医学信息,2019,32(12):109.[doi:10.3969/j.issn.1006-1959.2019.12.034]
　CUI Yan-zhao,WU Chun-quan.Therapeutic Effect of Thyroidectomy on Differentiated Thyroid Cancer[J].Journal of Medical Information,2019,32(19):109.[doi:10.3969/j.issn.1006-1959.2019.12.034]
[2]马秋晟.分化型甲状腺癌的诊断及治疗研究进展[J].医学信息,2020,33(08):48.[doi:10.3969/j.issn.1006-1959.2020.08.016]
　MA Qiu-sheng.Diagnosis and Treatment of Differentiated Thyroid Cancer[J].Journal of Medical Information,2020,33(19):48.[doi:10.3969/j.issn.1006-1959.2020.08.016]
[3]倪 剑.分化型甲状腺癌患者术后放射性131Ⅰ治疗效果的影响因素分析[J].医学信息,2020,33(22):114.[doi:10.3969/j.issn.1006-1959.2020.22.032]
　NI Jian.Analysis of Influencing Factors of Postoperative Radioactive 131ⅠTherapy in Patients with Differentiated Thyroid Cancer[J].Journal of Medical Information,2020,33(19):114.[doi:10.3969/j.issn.1006-1959.2020.22.032]
[4]唐嘉晨,郝玲玲,秦晓茹,等.全腔镜下甲状腺乳头状癌并发症Meta分析[J].医学信息,2021,34(04):78.[doi:10.3969/j.issn.1006-1959.2021.04.021]
　TANG Jia-chen,HAO Ling-ling,QIN Xiao-ru,et al.Meta-analysis of Complications of Papillary Thyroid Carcinoma Under Full Laparoscopic Surgery[J].Journal of Medical Information,2021,34(19):78.[doi:10.3969/j.issn.1006-1959.2021.04.021]

更新日期/Last Update: 1900-01-01